Peritonitis from facultative anaerobic gram-negative bacilli likely due to translocation of bacteria from gut in a patient undergoing peritoneal dialysis

Sreedhar Adapa,1 Srikanth Naramala,2 Harmandeep Singh Tiwana,1 Niraj Patel,3 Raman Verma,4 Narayana Murty Koduri,4 Venu Madhav Konala6
1The Nephrology group, Fresno, CA; 2Department of Rheumatology, Adventist Medical Center, Hanford, CA; 3Department of Internal Medicine, Adventist Medical Center, Hanford, CA; 4Department of Internal Medicine, Kaweah Delta Medical Center, Visalia, CA; 5Department of Psychiatry, Great Plains Health, North Platte, NE; 6Ashland Bellefonte Cancer Center, Ashland, KY, USA

Abstract
The peritonitis caused by gram-negative organisms is a serious complication encountered in patients undergoing peritoneal dialysis, often causing high morbidity and mortality. There has been recognition of peritonitis caused by uncommon organisms because of improved microbiological detection techniques. The healthcare providers involved in the management of these patients should be very vigilant. We report a rare case of peritonitis caused by Citrobacter freundii. A 42-year-old male on peritoneal dialysis for five years presented with abdominal pain and cloudy effluent. The peritoneal fluid analysis was consistent with abdominal tenderness with a peritoneal rub and guarding. The patient was treated with 2 courses of double antibiotic coverage with intraperitoneal cefazidime and oral ciprofloxacin, which failed to resolve the infection and hence resulted in the removal of the peritoneal dialysis catheter and dialysis modality change.

Introduction
Gram-negative organism peritonitis is a severe complication encountered in patients undergoing peritoneal dialysis, often causing high morbidity and mortality. The healthcare providers involved in the care of patients undergoing peritoneal dialysis should recognize that unusual organisms could cause peritonitis. We report the case of a 42-year-old male on peritoneal dialysis presenting with Citrobacter freundii peritonitis.

Case Report
A 42-year-old male on peritoneal dialysis presented with abdominal pain and cloudy effluent of one-day duration. The patient denied any fever and denied any in advent breach in the technique while making peritoneal dialysis connections. Moreover, the patient denied history of diarrhea or constipation. The patient has been on peritoneal dialysis for five years and had no prior history of peritonitis. Past medical history was significant for diabetes, hypertension, hyperlipidemia, hyperparathyroidism, and end-stage renal disease on peritoneal dialysis. Home medications included metoprolol 100 milligrams (mg) twice a day, nifedipine 60 mg extended-release daily, atorvastatin 80 mg daily, sevelamer 2400 mg three times a day with meals, calcitriol 0.5 micrograms (mcg) daily, gabapentin 100 mg daily at bedtime, cinacalcet 30 mg daily, insulin glargine 15 units daily, insulin sliding scale.

The vital signs on presentation were the temperature of 36.4 Celsius, pulse rate of 84 beats per minute, respiratory rate of 16 breath per minute, blood pressure of 158/95 mm Hg. Physical examination revealed abdominal tenderness with a peritoneal dialysis catheter in the right lower quadrant. There was no exit site drainage or redness along the tunnel and the rest of the physical examination was nonsignificant.

Laboratory analysis showed white blood cell count 10300 mm3, hemoglobin 11.2 gm/dl, platelet count 22300 mm3, sodium 138 mmol/l, potassium 4.5 mmol/l, bicarbonate 22 mmol/l, blood urea nitrogen 58 mg/dl, creatinine 11.6 mg/dl, albumin 3.3 g/dl. The peritoneal fluid effluent revealed peritoneal fluid white blood cells (WBC) 1837 cells/ul with 85% predominant neutrophils. Peritoneal fluid gram stain revealed >100 WBC, and no organisms were seen. The patient was started on empiric treatment for peritonitis with intraperitoneal vancomycin and cefazidime. Later on, peritoneal fluid culture grew Citrobacter freundii in both aerobic and anaerobic bottles. The sensitivities of Citrobacter freundii were listed in Table 2 done by VITEK 2 method.

The patient was treated with double antibiotic coverage of intraperitoneal cefazidime and oral ciprofloxacin for three weeks. The repeat peritoneal fluid cultures after finishing the antibiotic course yielded heavy growth of C. freundii again. The sensitivities of Citrobacter freundii are listed in Table 2 done. Another three weeks course
of double antibiotic treatment (intraperitoneal cefazidime and intravenous imipenem) was given, which failed to clear the organism. The symptoms resolved when peritoneal dialysis catheter was removed after failing two double antibiotic courses. Subsequently, he did not require a further course of antibiotics. The dialysis modality of the patient was then switched to hemo dialysis and the patient continues to be hemo dialysis dependent after two years of follow up.

Discussion

*C. freundii* belongs to the *Enterobacteriaceae* family, which accounts for more than 10% of cases of peritonitis. *Serratia, Pseudomonas/Providencia, indole positive Proteus/Acinetobacter/Morganella, Citrobacter, Enterobacter, and Hafnia* group of organisms (SPICE) are associated with peritonitis with high mortality, and morbidity. *Citrobacter* has low virulence and accounts for 4.8% of all *Enterobacteriaceae* peritonitis. C. freundii and *C. koseri* are the most pathogenic strains and cause seventy percent of human infections among the *Citrobacter* genus. Other medically important species in *Citrobacter* are *C. amalonaticus, C. farneri, C. braakii, C. werkmanni, and C. sedlakii*. *Citrobacter* is the rare cause of peritonitis, and *C. freundii* is the common species involved, frequently leads to peritoneal dialysis catheter removal despite repeated courses of double antibiotic coverage.4 Dialysis patients are prone to have gastrointestinal colonization from gram-negative bacteria, particularly *Citrobacter* compared to the general population. *Citrobacter* peritonitis tends to be polymicrobial in 10-15% episodes com-

| Author            | Year | Gender | Age/Duration | Dialysis | Polymicrobial culture | Dialsate | Treatment salvage | Catheter | Outcome                          |
|------------------|------|--------|--------------|----------|-----------------------|----------|-------------------|----------|----------------------------------|
| Dengisoglu et al.4 | 2008 | 33/F   | 96           | CAPD     | No                    | Positive | Intravenous Meropenem, Intraperitoneal Gentamicin | No       | Infection resolved and patient was switched to HD |
| Farinha et al.5   | 2013 | 65/M   | NA           | NA       | No                    | Positive | IV Cefazidime, IV piperacillin-tazobactam, IV Gentamicin | No       | Patient died for peritonitis before completion of antibiotic course and PD catheter removal |
| Kusaba et al.6    | 2012 | 66/M   | 12           | NA       | Yes                   | Positive | Intrapерitoneal Cefazidime, Intrapерitoneal Vancomycin, Intraperitoneal Ciprofloxacin | No       | Infection resolved and patient was switched to HD |
| Oh et al.11       | 2015 | 34/F   | 48           | CAPD     | Yes                   | Positive | Intravenous Gentamicin | No       | Infection resolved and patient was switched to HD |
| Kataria et al.12  | 2015 | 76/M   | 6            | CCPD     | No                    | Positive | Oral Ciprofloxacin and Intraperitoneal Gentamicin | Yes      | Infection resolved with antibiotics |

CAPD, continuous ambulatory peritoneal dialysis; CCPD, continuous cyclic peritoneal dialysis; NIPD, nocturnal intermittent peritoneal dialysis; HD, hemodialysis; NA, not available.
pared to 13-30% episodes in other infections. We summarized all the cases listed as *C. freundii* peritonitis on literature review from PubMed in Table 3. 

The patients who are at risk of developing infections from *Citrobacter* are elderly, immunocompromised, debilitated, and have multiple comorbidities. Invasive genitourinary procedures increase the risk of colonization and infection by this organism. The mode of transmission in peritonitis could be from microbial transmural migration from the gastrointestinal tract by their colonization accounting for 45% compared to 5-10% from other organisms. It is associated with constipation and/or diarrhea in 46% of episodes in a case series. It is implicated in causing bacteremia, septicemia, superficial skin infections, brain abscess, meningitis, and urinary tract infections. *Citrobacter* is typically isolated using standard microbiological techniques using Mueller Hinton agar by the standard disc diffusion method recommended by the Clinical and Laboratory Standards Institute (CLSI). The genus *Citrobacter* can be identified by culture of the blood or body fluid and most of them ferment glucose with the production of gas and exclusively utilize citrate as a carbon source. Species differentiation is done by biochemical tests, DNA hybridization, and Vitek GNI+ card.

ISPD (International Society of peritoneal dialysis) 2016 guidelines recommends treating SPICE organisms for three weeks with double antibiotic coverage as per sensitivities. There is a high level of resistance to ampicillin and first-generation cephalosporin in a bacterial strain of *C. freundii* attributed to ampC gene as in our patient. The organisms are often sensitive to quinolones, aminoglycosides, and carbapenems. However, in our patient, *Citrobacter freundii* was resistant to aminoglycosides from the beginning and developed intermediate sensitivity to fluoroquinolones. The mortality rate associated with *Citrobacter* peritonitis is 18%. The dialysis modality was switched in 89% of surviving patients with *Citrobacter* peritonitis over twelve months follow up.

### Conclusions

This case highlights that rare organisms like *Citrobacter freundii* can cause peritonitis likely due to the translocation of bacteria from the gut. There has been increased identification of peritonitis from SPICE organisms due to recent advances in microbiological techniques. Double antibiotic treatment is required for SPICE organisms as per ISPD.

### References

1. Liu LH, Wang NY, Wu AY, et al. *Citrobacter freundii* bacteremia: Risk factors of mortality and prevalence of resistance genes. Microbiol Immunol Infect 2018;51:565-72.
2. Ranjan KP, Ranjan N. *Citrobacter*: An emerging health care associated urinary pathogen. Urol Ann 2013;5:313-4.
3. Janda JM, Abbott SL, Cheung WK, et al. Biochemical identification of citrobacter in the clinical laboratory. J Clin Microbiol 1994;32:1850-4.
4. Kataria A, Saad E. Severe peritonitis caused by *Citrobacter freundii* and successful treatment with double antibiotic coverage. Indian J Nephrol 2015;25:117.
5. Szeto CC, Chow VY, Chow KM, et al. Enterobacteriaceae peritonitis complicating peritoneal dialysis: a review of 210 consecutive cases. Kidney Int 2006;69:1245-52.
6. Brenner DJ, Grimont PA, Steigerwalt AG, et al. Classification of *Citrobacter* farmeri sp. nov., *Citrobacter* youngae sp. nov., *Citrobacter* sedlakii sp. nov., and three unnamed *Citrobacter* genospecies. Int J Syst Bacteriol 1993;43:645-58.
7. Chao CT, Lee SY, Yang WS, et al. *Citrobacter* peritoneal dialysis peritonitis: rare occurrence with poor outcomes. Int J Med Sci 2013;10:1092.
8. Dervisoglu E, Yumuk Z, Yegenaga I. *Citrobacter freundii* peritonitis and tunnel infection in a patient on continuous ambulatory peritoneal dialysis. J Med Microbiol 2008;57:125-7.
9. Farinha A, Vaz A, Assuncao J, et al. Bactérias raras como causa de peritonite em diálise peritoneal: A experiência de um centro. Portug J Nephrol Hypertens 2013;27:187-95.
10. Kusaba T, Kirita Y, Ishida R, et al. Morphological analysis of biofilm of *peritoneal dialysis* catheter in refractory peritonitis patient. CEN Case Rep 2012;1:50-4.
11. Oh TR, Ma SK, Kim SW. Unusual CAPD *Citrobacter freundii* Peritonitis Complicated by a Fungal Infection, Identified by 16s Ribosomal RNA Gene Sequencing. Korean J Med 2015;88:593-7.
12. Prowant B, Nolph K, Ryan L, et al. Peritonitis in continuous ambulatory peritoneal dialysis: analysis of an 8-year experience. Nephron 1986;43:105-9.
13. Singharetam W, Holley JL. Acute treatment of constipation may lead to transmural migration of bacteria resulting in gram-negative, polymicrobial, or fungal peritonitis. Periton Dialysis Int 1996;16:423.
14. Wayne P. Clinical Laboratory Standard Institute (CLSI). Performance standards for antimicrobial susceptibility testing: Twentieth informational supplement. CLSI document M100–S20; 2010.
15. Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Periton Dialysis Int 2016;36:481-508.